Callan Family Office LLC Invests $1.30 Million in Axon Enterprise, Inc $AXON

Callan Family Office LLC acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,316 shares of the biotechnology company's stock, valued at approximately $1,298,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Edgewood Management LLC acquired a new stake in Axon Enterprise in the 4th quarter valued at about $846,516,000. Wellington Management Group LLP grew its position in shares of Axon Enterprise by 326.9% during the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company's stock worth $874,463,000 after buying an additional 1,179,038 shares in the last quarter. Norges Bank purchased a new stake in shares of Axon Enterprise during the fourth quarter worth approximately $515,764,000. BlackRock Inc. increased its stake in shares of Axon Enterprise by 4.3% during the second quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company's stock worth $4,672,432,000 after buying an additional 345,365 shares during the period. Finally, Styrax Capital LP acquired a new stake in Axon Enterprise in the first quarter valued at approximately $84,938,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $627.75 on Monday. The company has a market capitalization of $51.00 billion, a P/E ratio of 260.48, a PEG ratio of 10.19 and a beta of 1.39. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. Axon Enterprise, Inc has a fifty-two week low of $339.01 and a fifty-two week high of $794.29. The stock has a 50-day simple moving average of $543.11 and a 200-day simple moving average of $476.99.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, topping the consensus estimate of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The company had revenue of $904.39 million for the quarter, compared to analyst estimates of $876.42 million. During the same quarter in the previous year, the company posted $2.12 earnings per share. The firm's revenue was up 35.3% compared to the same quarter last year. Equities research analysts expect that Axon Enterprise, Inc will post 2.04 earnings per share for the current year.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 13,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the completion of the sale, the president owned 169,125 shares in the company, valued at $82,609,106.25. This represents a 7.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CRO Cameron Brooks sold 1,242 shares of the firm's stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $500.00, for a total transaction of $621,000.00. Following the transaction, the executive directly owned 49,710 shares in the company, valued at $24,855,000. The trade was a 2.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 66,989 shares of company stock valued at $35,216,932. 4.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on AXON shares. Weiss Ratings reiterated a "hold (c-)" rating on shares of Axon Enterprise in a report on Wednesday, August 5th. Needham & Company LLC restated a "buy" rating on shares of Axon Enterprise in a report on Thursday, August 6th. Barclays lifted their price objective on shares of Axon Enterprise from $523.00 to $688.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Citizens Jmp restated a "market outperform" rating and set a $700.00 target price on shares of Axon Enterprise in a research note on Thursday, June 25th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Axon Enterprise in a report on Wednesday, July 22nd. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $730.92.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company's hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source